REFERENCES

1.

Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: a systematic review. JAMA. 2007;298(6):655-669.

2.

Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69(6):1158-1161.

3.

Data on file, DANCER Trial CSR. Genentech USA, Inc.

4.

Data on file, FDA approval letter, 02/2006. Genentech USA, Inc.

5.

Data on file, FDA approval letter, 04/2011. Genentech USA, Inc.

6.

Data on file, Label update approval letter, 01/2008. Genentech USA, Inc.

7.

Data on file, Label update approval letter, 10/2009. Genentech USA, Inc.

8.

Data on file, REFLEX Trial CSR. Genentech USA, Inc.

9.

Gomez-Puerta JA, Hernandez-Rodriguez J, Lopez-Soto A, Bosch X. Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. Chest. 2009;136(4):1101-1111.

10.

Langford CA. Vasculitis. J Allergy Clin lmmunol. 2010;125(2):S216-S225.

11.

Rituxan [package insert]. South San Francisco, CA: Biogen and Genentech USA, Inc.; 2019.

12.

Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-427.

13.

Stone JH, Merkel PA, Spiera R, et al; for the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. Download Article

14.

Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol. 2009;23(3):391-401.

15.

van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761-1766.